Is ACHC a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Acadia Healthcare (ACHC) rests on Structural demand for behavioral health: Mental-health and substance-use treatment remains chronically undersupplied in the US, giving Acadia a long runway of demand across its acute, residential, and addiction service lines. Revenue (2025) is ~$3.31B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Legal and regulatory exposure is the defining risk. Whether ACHC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue. The investment picture combines a genuinely strong demand backdrop for mental-health and addiction services with a growth model built on same-facility volume gains, higher revenue per patient day, and continued bed additions through de novo hospitals and joint ventures. Full-year 2025 revenue reached about $3.31 billion, up roughly 5 percent, and 2026 guidance points to $3.37 billion to $3.45 billion. Offsetting this are material risks: elevated patient-related litigation costs, a DOJ criminal subpoena tied to admissions and billing practices, a settled securities class action, and a leveraged balance sheet, all of which have kept the stock volatile and well below prior highs.
What's the case for buying ACHC?
1. Structural demand for behavioral health
Mental-health and substance-use treatment remains chronically undersupplied in the US, giving Acadia a long runway of demand across its acute, residential, and addiction service lines. Same-facility revenue rose about 7 percent in early 2026, driven by both higher patient days and higher revenue per patient day. As the largest pure-play operator, Acadia has scale advantages in payor contracting and site development.
2. Bed expansion and de novo growth
Acadia grows primarily by adding beds, opening new acute psychiatric hospitals, and forming joint ventures with health systems. This capital-intensive expansion has steadily lifted capacity beyond 12,500 beds. The acute inpatient segment, which grew revenue around 14 percent year over year in Q1 2026, is the main engine of this growth.
3. Guidance and margin trajectory
Management raised full-year 2026 adjusted EBITDA guidance to roughly $580 million to $615 million and adjusted EPS to $1.35 to $1.60, signaling confidence in operating trends. Adjusted EBITDA of about $144 million in Q1 2026 exceeded internal guidance. Reported earnings, however, remain pressured by higher legal, depreciation, and interest expenses.
4. Diversified payor and geographic mix
With operations spread across roughly 40 states and no facility exceeding about 4 percent of revenue, Acadia is insulated from any single market or facility shock. Its payor mix is government-weighted, which supports steady volume but ties results to Medicaid and Medicare rate dynamics.
What are the risks to ACHC?
Legal and regulatory exposure is the defining risk. Acadia agreed to pay $179 million to settle a securities class action tied to prior disclosures, faces a September 2024 DOJ Criminal Division grand jury subpoena related to its acute admissions, length of stay, and billing practices, and disclosed a sharp rise in patient-related litigation expense (roughly $116 million projected for 2025 versus $54 million in 2024). A 2024 New York Times investigation alleged patients were improperly detained, and a May 2026 California jury awarded $105 million in a retaliatory-termination case. The company also carries meaningful leverage, with total debt around $2.5 billion and net leverage near 3.9x adjusted EBITDA, and took a large goodwill impairment in late 2025. Heavy Medicaid and Medicare reliance leaves it exposed to reimbursement-rate and policy changes.
How is ACHC valued? (as of July 2026)
Snapshot for ACHC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025): ~$3.31B
- 2026 revenue guidance: ~$3.37B to $3.45B
- 2026 adj. EBITDA guidance: ~$580M to $615M
- 2026 adj. EPS guidance: ~$1.35 to $1.60
- Market cap: ~$2.8B
- Net leverage: ~3.9x adj. EBITDA
Acadia trades around $30 per share after a volatile year that saw the stock swing from roughly $11 to $33, reflecting litigation and guidance concerns. On a low-single-digit forward EBITDA multiple and mid-teens forward P/E against its guidance, the market is pricing meaningful legal and reimbursement uncertainty. Reported earnings remain depressed by legal and interest costs even as adjusted metrics grow.
How do you decide if ACHC is a buy?
Rather than asking whether ACHC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ACHC indirectly through an index or sector ETF before adding more.
For the full picture, see the ACHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ACHC against your real portfolio and see your actual exposure before deciding.
The bottom line on ACHC
The bottom line: Acadia Healthcare's story right now is Structural demand for behavioral health, with revenue (2025) at ~$3.31B. If you believe that narrative continues, the call is about sizing ACHC sensibly and checking overlap with what you own; if you doubt it (the risk: legal and regulatory exposure is the defining risk.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ACHC with Walnut
Use Acadia Healthcare as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ACHC a good stock to buy right now?
+
The case for Acadia Healthcare right now is Structural demand for behavioral health, with revenue (2025) at ~$3.31B. If you believe that thesis holds, ACHC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is legal and regulatory exposure is the defining risk. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Acadia Healthcare do?
+
Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds
What are the main risks of ACHC?
+
Legal and regulatory exposure is the defining risk. Acadia agreed to pay $179 million to settle a securities class action tied to prior disclosures, faces a September 2024 DOJ Criminal Division grand jury subpoena related to its acute admissions, length of stay, and billing practices, and disclosed a sharp rise in patient-related litigation expense (roughly $116 million projected for 2025 versus $54 million in 2024). A 2024 New York Times investigation alleged patients were improperly detained, and a May 2026 California jury awarded $105 million in a retaliatory-termination case. The company also carries meaningful leverage, with total debt around $2.5 billion and net leverage near 3.9x adjusted EBITDA, and took a large goodwill impairment in late 2025. Heavy Medicaid and Medicare reliance leaves it exposed to reimbursement-rate and policy changes.
What does Acadia Healthcare do?
+
Acadia Healthcare is the largest pure-play behavioral healthcare provider in the US. It operates acute inpatient psychiatric hospitals, residential treatment centers, specialty facilities, and comprehensive treatment centers for opioid-use disorder, spanning roughly 277 facilities and more than 12,500 beds.
How does Acadia Healthcare make money?
+
It earns revenue from patient care across its four service lines, billed largely to government payors. Medicaid accounts for about 58 percent of revenue, commercial insurers about 25 percent, and Medicare roughly 14 percent, with revenue driven by patient days and revenue per patient day.
How large is Acadia Healthcare?
+
Acadia generated about $3.31 billion in revenue in 2025 and guides to $3.37 billion to $3.45 billion in 2026. Its market capitalization is roughly $2.8 billion, and it operates across about 40 states and Puerto Rico.
What is driving Acadia's growth?
+
Growth comes mainly from same-facility volume and pricing gains plus bed expansion through new acute psychiatric hospitals and joint ventures with health systems. The acute inpatient segment has been the fastest-growing service line, up around 14 percent year over year in early 2026.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ACHC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.